The purpose of the Developmental Research Program (DRP) is to identify and support first-rate, pioneering translational projects in lymphoma that, despite their potential, are not yet mature for full program status. All members of the research community at City of Hope and University of Alabama Birmingham (UAB) are encouraged to consider the opportunity. We have requested $50,000 per year to support this program, and City of Hope and UAB will match these funds annually by $100,000 and $25,000, respectively. At least two researchers per year receive awards, which are granted for up to two years. Funds can be devoted to research supplies and minor equipment, personnel costs, and relevant meeting expenses. Promising investigations may replace SPORE research projects that have either acquired funding as independent R01/P01 projects, or those that have not satisfactorily progressed. Drs. Larry Kwak, Wing (John) Chan, and Ravi Bhatia, longstanding leaders in their field, are the Developmental Program Directors. A request for applications will be advertised and sent to the entire City of Hope and UAB research committees. Proposals from women and minority applicants are encouraged. Proposed projects are reviewed on the basis of scientific merit, likelihood of benefit to lymphoma patients, qualifications of key personnel, and the potential for interaction with the projects and cores of the City of Hope Lymphoma SPORE. Selected projects are fully integrated into the overall SPORE. Investigators funded through the DRP fully participate in SPORE activities, including monthly meetings, allowing an open exchange of ideas and research goals. The SPORE also enhances interactions between DRP researchers and investigators at other SPOREs and institutions. Funded scientists present regular updates on their progress, receiving feedback and any needed problem solving. Over the last four years, projects under the DRP have been reflective of our innovative research programs in lymphoma. Data have contributed toward major specific aims in Projects 1 and 4 of the current SPORE and have generated substantial progress. We are eager to assist a new round of investigators by helping to bring to fruition studies with potential benefit to lymphoma patients and possibly those with other cancers, as well.

Public Health Relevance

The Developmental Research Program fosters promising translational research projects in lymphoma that are currently not yet mature for full program status. By cultivating these studies and facilitating interactions and collaborations within and beyond the SPORE, this program will place promising investigations in a position to reach their potential and develop means to reduce morbidity and mortality among lymphoma patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Herrmann, Andreas; Lahtz, Christoph; Nagao, Toshikage et al. (2017) CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res 77:5118-5128
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Herrera, Alex F; Armand, Philippe (2017) Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol 35:3877-3887
Won, Haejung; Moreira, Dayson; Gao, Chan et al. (2017) TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol 102:423-436
Gibson, Christopher J; Lindsley, R Coleman; Tchekmedyian, Vatche et al. (2017) Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol 35:1598-1605
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2017) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant :
Urak, Ryan; Walter, Miriam; Lim, Laura et al. (2017) Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer 5:26
Zhang, Chunyan; Xin, Hong; Zhang, Wang et al. (2016) CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44:913-923
Beharry, Andrew A; Lacoste, Sandrine; O'Connor, Timothy R et al. (2016) Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker. J Am Chem Soc 138:3647-50

Showing the most recent 10 out of 88 publications